🇺🇸 FDA
Patent

US 8916159

Selenocysteine mediated hybrid antibody molecules

granted A61KA61K47/68A61K47/6809

Quick answer

US patent 8916159 (Selenocysteine mediated hybrid antibody molecules) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 23 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K47/68, A61K47/6809, A61K47/6811, A61K47/6849